Presenting poster at SITC 

Lytix Biopharma AS ("Lytix"), a clinical-stage company with an in situ
vaccination technology platform, announces data showing that the Company's
LTX-315 induces immunotherapeutic and antimetastatic activity in a preclinical
breast cancer model that is resistant to immune checkpoint inhibitors. The data
will be presented November 13th, 2021, as a poster at the Society for
Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021).

LTX-315 displays anticancer effects against metastatic lesions in the lungs in
the triple negative breast cancer model

The data presented at SITC is published in a scientific article in
OncoImmunology entitled "LTX-315-enabled, radiotherapy-boosted immunotherapeutic
control of breast cancer by NK cells". 

In this study, the anticancer effect of LTX-315 in a triple negative breast
cancer (TNBC) model that were resistant to checkpoint inhibitor was
investigated. Among the different subtypes of breast cancer, TNBC is the most
difficult to treat. The TNBC model has several characteristics that make it a
suitable experimental animal model for human TNBC.  

In the TNBC model, LTX-315 alone displayed anticancer effects against metastasis
to the lungs. Earlier preclinical studies have clearly shown the involvement of
T cells in the anticancer effect of LTX-315. Here, it was also documented that
LTX-315's anticancer effects involved NK cell activity. The effect of LTX-315
was further improved when combined with radiotherapy and checkpoint inhibitors.

Collaborative research effort 

The study was a collaborative research effort between Lytix and the research
groups of Drs. Lorenzo Galluzzi and Sandra Demaria at Weill Cornell Medicine,
New York. Demaria serves as a paid scientific advisory board member for Lytix
Biopharma.

"Intratumoral LTX-315 controlled metastatic dissemination in an immunocompetent
model of triple negative breast cancer that is resistant to immune checkpoint
inhibitors, at least in part by engaging NK-cell dependent anticancer immunity.
Our findings expand the mechanisms whereby LTX-315 controls breast cancer
progression," Galluzzi said.

Scientific evidence of anticancer effects

"These findings provide further scientific evidence for the broad anticancer
effect of LTX-315 and the potential to combine LTX-315 with checkpoint
inhibitors and conventional therapy," said Øystein Rekdal (CEO in Lytix
Biopharma). He continues: "We are proud to publish these promising data,
together with the excellent research teams at Weil Cornell Medicine, led by
Sandra Demaria and Lorenzo Galluzzi, in OncoImmunology, a leading journal within
the cancer immunology field".

Sandra Demaria comments: "LTX-315 caused a considerable decrease in the number
of macroscopic pulmonary metastases formed by progressing tumors. These study
results are consistent with the marked capacity of LTX-315 to elicit tumor
specific immunity - through eliciting immunogenic cell death (ICD) in malignant
cells documented in previous studies".

The poster will be available on Lytix webpage on Saturday November 13th, 2021. 

For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358 
E-mail: Oystein.Rekdal@lytixbiopharma.com

Lytix in brief: Based in Oslo, Norway, Lytix Biopharma is a clinical stage
biotech company developing novel cancer immunotherapies, an area within cancer
therapy that is aimed at activating the patient's immune system to fight cancer.
The Company's technology is based on pioneering research in "host defense
peptides" - nature's first line of defense towards foreign pathogens. Lytix
Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule
representing a new and superior in situ therapeutic vaccination principle to
boost anti-cancer immunity, with the potential to be the ideal combination
partner with other types of immunotherapy.